Update οn the diagnosis and management of systemic lupus erythematosus.

Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930. 

All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.

Morand EF, et al. Lancet Rheum. 2022;4(4):E282-E292.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases.

Ramaswamy M, et al. Int J Mol Sci. 2021;22(20):11286.

Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study.

Ruiz-Arruza I, et al. Arthritis Care Res. 2018;70(4):582-591.

SLE mortality remains disproportionately high, despite improvements over the last decade.

Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.